StonvexLoading…
StonvexStonvexStonvexCore line items from GYRE's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
| Metric | Annual 2025 2025-12-31 | Annual 2024 2024-12-31 | Annual 2023 2023-12-31 | Annual 2022 2022-12-31 |
|---|---|---|---|---|
Revenue | $116.59M | $105.76M | $113.45M | $102.29M |
Operating Income | $11.49M | $16.16M | $-67.23M | $9.20M |
Net Income | $9.88M | $17.90M | $-85.48M | $4.31M |
EPS (Diluted) | $0.02 | $0.05 | $-1.41 | $0.03 |
Total Assets | $166.13M | $125.41M | $116.54M | $84.75M |
Total Liabilities | $23.85M | $27.00M | $38.06M | $12.54M |
Cash & Equivalents | $37.07M | $11.81M | $33.51M | $25.18M |
Free Cash Flow OCF − CapEx | $-180.00K | $-5.96M | $17.38M | $5.69M |
Shares Outstanding | 91.31M | 86.31M | 76.60M | 63.59M |